Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST StudyPaola Guglielmelli, Tiziano Barbui, Maria Chiara Finazzi et al.|Blood Advances|2021Cited by 66
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS scoreTiziano Barbui, Alessandro M. Vannucchi, Arianna Ghirardi et al.|Blood Cancer Journal|2022Cited by 14
The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary MyelofibrosisTiziano Barbui, Björn Andréasson, Arianna Ghirardi et al.|Blood|2021Cited by 2
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registryPaola Guglielmelli, Tiziano Barbui, Arianna Ghirardi et al.|HemaSphere|2025Cited by 1